3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Breast Neoplasms
558
Carcinoma, Non-Small-Cell Lung
517
Prostatic Neoplasms
335
Colorectal Neoplasms
273
Neoplasms
268
Multiple Myeloma
267
Leukemia, Myeloid, Acute
224
Squamous Cell Carcinoma of Head and Neck
217
Lung Neoplasms
210
Neoplasm Metastasis
205
Carcinoma, Hepatocellular
197
Melanoma
175
Triple Negative Breast Neoplasms
173
Pancreatic Neoplasms
171
Recurrence
152
Ovarian Neoplasms
152
Lymphoma
141
Glioblastoma
134
Brain Neoplasms
133
Sarcoma
130
Carcinoma, Renal Cell
129
Stomach Neoplasms
125
Lymphoma, Large B-Cell, Diffuse
125
Leukemia, Lymphocytic, Chronic, B-Cell
125
Head and Neck Neoplasms
125
Rectal Neoplasms
109
Precursor Cell Lymphoblastic Leukemia-Lymphoma
109
Myelodysplastic Syndromes
103
Uterine Cervical Neoplasms
100
Urinary Bladder Neoplasms
100
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
1 year
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled